Communications Biology (Oct 2021)
LIFR inhibition enhances the therapeutic efficacy of HDAC inhibitors in triple negative breast cancer
- Mengxing Li,
- Suryavathi Viswanadhapalli,
- Bindu Santhamma,
- Uday P. Pratap,
- Yiliao Luo,
- Junhao Liu,
- Kristin A. Altwegg,
- Weiwei Tang,
- Zexuan Liu,
- Xiaonan Li,
- Behnam Ebrahimi,
- Hui Yan,
- Yi Zou,
- Swapna Konda,
- Gangadhara R. Sareddy,
- Zhenming Xu,
- Yidong Chen,
- Manjeet K. Rao,
- Andrew J. Brenner,
- Virginia G. Kaklamani,
- Rajeshwar R. Tekmal,
- Gulzar Ahmed,
- Ganesh V. Raj,
- Klaus J. Nickisch,
- Hareesh B. Nair,
- Ratna K. Vadlamudi
Affiliations
- Mengxing Li
- Department of Obstetrics and Gynecology, University of Texas Health San Antonio
- Suryavathi Viswanadhapalli
- Department of Obstetrics and Gynecology, University of Texas Health San Antonio
- Bindu Santhamma
- Evestra, Inc
- Uday P. Pratap
- Department of Obstetrics and Gynecology, University of Texas Health San Antonio
- Yiliao Luo
- Department of Obstetrics and Gynecology, University of Texas Health San Antonio
- Junhao Liu
- Department of Obstetrics and Gynecology, University of Texas Health San Antonio
- Kristin A. Altwegg
- Department of Obstetrics and Gynecology, University of Texas Health San Antonio
- Weiwei Tang
- Department of Obstetrics and Gynecology, University of Texas Health San Antonio
- Zexuan Liu
- Department of Obstetrics and Gynecology, University of Texas Health San Antonio
- Xiaonan Li
- Department of Obstetrics and Gynecology, University of Texas Health San Antonio
- Behnam Ebrahimi
- Department of Obstetrics and Gynecology, University of Texas Health San Antonio
- Hui Yan
- Department of Microbiology, Immunology and Molecular Genetics, University of Texas Health San Antonio
- Yi Zou
- Greehey Children’s Cancer Research Institute, University of Texas Health San Antonio
- Swapna Konda
- Evestra, Inc
- Gangadhara R. Sareddy
- Department of Obstetrics and Gynecology, University of Texas Health San Antonio
- Zhenming Xu
- Mays Cancer Center, University of Texas Health San Antonio
- Yidong Chen
- Mays Cancer Center, University of Texas Health San Antonio
- Manjeet K. Rao
- Mays Cancer Center, University of Texas Health San Antonio
- Andrew J. Brenner
- Mays Cancer Center, University of Texas Health San Antonio
- Virginia G. Kaklamani
- Mays Cancer Center, University of Texas Health San Antonio
- Rajeshwar R. Tekmal
- Department of Obstetrics and Gynecology, University of Texas Health San Antonio
- Gulzar Ahmed
- Evestra, Inc
- Ganesh V. Raj
- Departments of Urology and Pharmacology, University of Texas Southwestern Medical Center at Dallas
- Klaus J. Nickisch
- Evestra, Inc
- Hareesh B. Nair
- Evestra, Inc
- Ratna K. Vadlamudi
- Department of Obstetrics and Gynecology, University of Texas Health San Antonio
- DOI
- https://doi.org/10.1038/s42003-021-02741-7
- Journal volume & issue
-
Vol. 4,
no. 1
pp. 1 – 14
Abstract
Li, Viswanadhapalli et al utilized multiple in vitro, ex vivo and in vivo models of TNBC to investigate LIFR inhibition. The authors reported that HDAC inhibition in TNBC cells led to an increase of LIFR expression and over activation of the downstream signaling elements (e.g., STAT3, mTOR, AKT), enhancing the aggressive potential of TNBC cells, and an LIFR inhibitor, EC359, synergistically enhanced the efficacy of HADC inhibitors in suppressing TNBC in vitro and in vivo.
